1. Home
  2. GNPX vs KUST Comparison

GNPX vs KUST Comparison

Compare GNPX & KUST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

BUY

Current Price

$1.84

Market Cap

2.2M

Sector

Health Care

ML Signal

BUY

Logo Kustom Entertainment Inc. Common Stock

KUST

Kustom Entertainment Inc. Common Stock

HOLD

Current Price

$3.60

Market Cap

2.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
KUST
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.4M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
GNPX
KUST
Price
$1.84
$3.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 164.8K
16.1K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $14,577,600.00
Revenue This Year
N/A
$40.06
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.42
$3.52
52 Week High
$9.99
$224.00

Technical Indicators

Market Signals
Indicator
GNPX
KUST
Relative Strength Index (RSI) 23.85 44.42
Support Level $0.80 N/A
Resistance Level $2.12 $4.13
Average True Range (ATR) 0.21 0.34
MACD -0.03 -0.38
Stochastic Oscillator 4.39 7.04

Price Performance

Historical Comparison
GNPX
KUST

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About KUST Kustom Entertainment Inc. Common Stock

Kustom Entertainment Inc provides live event production and ticketing technology services. The company operates in two segments: video solutions and entertainment. The Video Solutions Segment represents the Company's legacy operations and includes the development, manufacture, and sale of digital video imaging and storage products, disinfectant, and related safety products for use in law enforcement, security, and commercial applications. The Entertainment Segment operates a secondary ticketing platform through TicketSmarter.com, acting as an intermediary between ticket buyers and sellers. In addition, this segment includes live event production and promotion activities, including the Country Stampede music festival and other entertainment events.

Share on Social Networks: